The new COVID-19 vaccine manufactured by Sanofi and GlaxoSmithKline(GSK) is highly effective against severe cases of COVID-19 and prevents 100 percent of hospitalizations.
Early data from the latest late-stage trials show the Vaccine, Vidprevtyn is 100% effective against severe Covid-19 disease, including hospitalizations. Also with 75 percent efficacy against moderate to severe cases and 58% effective at preventing Covid-19 symptoms.
The phase 3 trials to test the vaccine enrolled more than 10,000 adults. A separate study is assessing a third dose of the vaccine as a booster.
The data from booster trials showed that the Sanofi-GSK vaccine could increase antibodies up to 30 times in people who’d gotten Pfizer, Moderna, Johnson & Johnson, and AstraZeneca shots.
Vidprevtyn is a protein subunit vaccine, which uses harmless protein fragments that teach the immune system how to spot and fight off the SARS-CoV-2 virus.
The vaccines can be stored at refrigerator temperatures, making them easier to use in areas that don’t have access to ultracold storage.
The manufacturers are seeking approval for the vaccine to be used as a regular two-dose shot and booster shot.
The company says it has produced and released 100 million doses and plans to supply up to 400 million more doses.